-
Hexvix® improves bladder cancer free survival - data to be presented at the EAU congressPhotocure and Ipsen to co-sponsor two symposia on bladder cancer management. Data on impact of Hexvix® on long term recurrence rates to be prestented at European Association of Urology (EAU) Congress, Paris24 Feb 2012 -
Photocure announces new commercial strategy for Hexvix®, the innovative product for improved detection of bladder cancer• Strategic collaboration with Ipsen for marketing rights in Europe and the rest of the world except Nordics and the US • Photocure to commercialise the product directly in the US market27 Sep 2011
-
Photocure Launches Allumera® A New, Dynamic Cosmetic For Achieving Timeless SkinAllumera Represents The First In A New Class Of Photodynamic Cosmetics22 Jun 2011
-
Photocure initiates enrollment into phase II trial of Cevira® for cervical HPV infectionFirst study to evaluate optimal dose of novel integrated drug-delivery device First novel therapeutic treatment option for highly prevalent cervical HPV infections and precancerous lesions22 Jun 2011
-
Hexvix®/Cysview™ demonstrates long term benefit12 May 2011
-
British Journal of Urology publishes paper on Hexvix®Demonstrates significant reduction in recurrence of bladder cancer23 Mar 2011
-
Photocure announces positive preliminary results from the Allumera™ consumer trialAllumera™ shows significant improvements in appearance of skin compared to light29 Nov 2010
